Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 1,101–1,200 of 2,053
Vågenes, S. T., Graue, M., Igland, J., Kolltveit, B. H., & Riise, H. K. R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0312485 · Cited by 1
Impact of Personal Health Records on Diabetes Management: A Propensity Score Matching Study
Ono, Y., Okada, H., Kitagawa, N., Majima, S., Okamura, T., Senmaru, T., Ushigome, E., Nakanishi, N., Hamaguchi, M., & Fukui, M. (2024) · Diabetology · doi:10.3390/diabetology5070047 · Cited by 2
“To accomplish this, a fundamental focus on education emphasizing lifestyle improvement is necessary, regardless of the treatment program [1,2].”
Expanding Drug Indications: Strategic Lifecycle Management vs. Evergreening in SGLT2 Inhibitors
Shimmura, K. (2024) · Journal of IP in Practice · doi:10.5750/jipp.v1i1.2216 · Cited by 1
DIABETIC FOOT ULCER PREVENTION THROUGH WORKPLACE WELLNESS PROGRAMS: CONCEPTUAL PERSPECTIVE
Bidin, A. A. M., Yen, N. S., & Noor, A. A. M. (2024) · Social Security Management Journal · doi:10.32890/ssmj2024.1.2.4 · Cited by 1
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2025) · Die Diabetologie · doi:10.1007/s11428-024-01276-9 · Cited by 1
Emoto, R., Igeta, M., Matsui, K., Ishii, K., Takamura, T., & Matsui, S. (2025) · Journal of the Royal Statistical Society Series C (Applied Statistics) · doi:10.1093/jrsssc/qlae072 · Cited by 2
Brain lipidomic profiles of sleep enhancement through co‐administration of alprazolam and CGS21680
Zhang, Y., Xia, X., Jin, Q., Yang, G., Cao, M., Zong, X., Shi, J., Wang, C., & Li, L. (2025) · FEBS Letters · doi:10.1002/1873-3468.70009 · Cited by 1
“The combination of Alp and CGS as sleep medications can reduce dosing frequency, thereby enhancing patient compliance with treatment regimens [25].”
The Long-Term Cost-Effectiveness of Oral Semaglutide Versus Lower-Cost Liraglutide in the UK
Elnaggar, M., Mansinho, J. N., Malkin, S. J. P., Whitaker, J. S., Hunt, B., Glah, D. R., MacLellan, M., & Ali, S. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01691-1 · Cited by 1
“…disease or high cardiovascular risk has been recommended in guidelines published by the European Association for the Study of Diabetes (EASD), with oral semaglutide associated with cardiovascular safety in PIONEER 6 and cardiovascular benefits being evaluated in the ongoing SOUL study [1, 12, 15].”
InfluentialLEWIS, G. A., Hughes, D. M., Irving, G. J., Wilding, J. P. H., & Hardy, K. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16257 · Cited by 1
Pacheco, S. T., Weber, F. L. R., Greene, E. J. D., & Valdivia, G. G. (2025) · Acta Médica Grupo Ángeles · doi:10.35366/119342 · Cited by 2
Valcarce, I. D., González, M. M. P., García, C. F., Lindström, J., Zaletel, J., Giacomozzi, C., Tolika, F., Hidalgo, I. R., & Lana, A. (2025) · BMC Public Health · doi:10.1186/s12889-025-22246-w · Cited by 4
“Type 2 diabetes mellitus (T2DM) is a highly heterogeneous non-communicable chronic disease with a variable age of onset, associated with an undetermined degree of obesity and insulin resistance, and with tendency to develop health-and life-threatening complications [1].”
Liu, X., Zhang, Y., Zhao, L., Duan, Y., Hu, Z., Bao, L., & Jin, P. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01737-4 · Cited by 2
Liu, W., Yang, K., Lin, Y., Lu, C., Liu, J., Zhou, H., Wang, J., Zhang, T., Yao, L., Qi, H., et al. (2025) · Clinical Pharmacokinetics · doi:10.1007/s40262-025-01501-8 · Cited by 2
Snoek, F. J., Galstyan, G. R., Khan, N., Tirosh, A., Kesavadev, J., Vargas‐Uricoechea, H., Baghous, H., Mabunay, M. A., Grulović, N., Msihid, J., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16415 · Cited by 1
Sex-related differences - from pharmacology to clinical research methodology
Papiež, A., Čechová, Z., & Rychlíčková, J. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.019 · Cited by 1
Alicic, R. Z., & Neumiller, J. J. (2025) · Cardiology Clinics · doi:10.1016/j.ccl.2024.12.003 · Cited by 1
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2025) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2490-5208 · Cited by 1
Brož, J. (2025) · Vnitřní lékařství · doi:10.36290/vnl.2025.026 · Cited by 1
Luo, S., Liu, H., Li, Z., Zhou, Y., He, S., Zhang, D., Qin, S., & Wen, X. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07716-y · Cited by 1
Sleep and Circadian Rhythms and Metabolism
Chang, A., Kaki, P. C., Yuan, R. K., Depner, C. M., & Buxton, O. M. (2025) · Oxford University Press eBooks · doi:10.1093/oxfordhb/9780197602751.013.42 · Cited by 1
Erbakan, M., & Torun, C. (2025) · Mediterranean Journal of Nutrition and Metabolism · doi:10.1177/1973798x251349603 · Cited by 1
Olson, J. J., Beaulieu, D. B., Bennett, A. L., et al. (2025) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x251349383 · Cited by 1
“8,9 12 There is a need to understand how patterns of care for patients who seeking care for in fl ammatory bowel disease has shifted with increased access to telecare.”
Explainable AI for Diabetes Risk Stratification Using Severity Index Indicators
U, R. M. V., Pushpalatha, M., & Avarebeel, S. (2025) · International Conference on Trends in Engineering Systems and Technologies (ICTEST) · doi:10.1109/ictest64710.2025.11042791 · Cited by 1
Expert Consensus Statement on Simplified Glycemic Care in Patients With Type 2 Diabetes Mellitus
Sethi, B. K., Chowdhury, S., Jain, S. M., Zargar, A. H., Chadha, M. D., Bhattacharyya, A., Shaikh, S. S., Makkar, B. M., Chawla, M. S., Kalra, P., et al. (2025) · Cureus · doi:10.7759/cureus.87002 · Cited by 1
“Metformin, combined with SGLT-2 inhibitors, is advised as the first-line treatment, while GLP-1 receptor agonists are suggested as second-line agents to reduce albuminuria and cardiovascular risk [10,11].”
InfluentialTIWASKAR, M. H., Hwu, C., Lim, M., Bhandary, A., & Chang, I. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01770-3 · Cited by 1
Extinguishing the Fire: Treating Pediatric Type 2 Diabetes by Targeting Obesity Treatment
Bensignor, M. O., Hsia, D. S., Name, M. A. V., Jastreboff, A. M., & Ryder, J. R. (2025) · Diabetes Care · doi:10.2337/dci25-0031 · Cited by 2
la Cruz, A. E. C.-D., Quiroz-Gómez, S., Landero-Jiménez, R., Guzmán‐Priego, C. G., & Jiménez-Sastré, A. (2025) · Cardiovascular and Metabolic Science · doi:10.35366/120544 · Cited by 1
Dimopoulou, M., Androutsos, O., Kipouros, M., Bargiota, Α., & Gortzi, O. (2025) · Diabetology · doi:10.3390/diabetology6080072 · Cited by 1
“However, meal testing to provide more diabetic-friendly food choices for patients is not a new concept due to the fact that medical nutrition therapy (MNT) has existed since 2022 [24].”
Sasaki, H., Yagi, K., Uratsuji, Y., Fujii, T., & Koide, M. (2025) · Cureus · doi:10.7759/cureus.89686 · Cited by 2
“Owing to its low cost and robust evidence supporting the reduction in macrovascular complications in patients with type 2 diabetes, metformin has long been recommended as a first-line therapy in major clinical guidelines [3,4].”
Hoca, E., & Kalaycı, N. (2025) · Medical Bulletin of Haseki · doi:10.4274/haseki.galenos.2025.14633 · Cited by 1
García-Ulloa, A. C., Pérez-Peralta, L., Urbina-Arronte, L. E., Cárdenas-Fragoso, J. L., Landa-Anell, M. V., Melgarejo-Hernández, M. A., Gil, V., Ponce‐de‐León, S., & Hernández-Jiménez, S. C. (2025) · Archives of Medical Research · doi:10.1016/j.arcmed.2025.103271 · Cited by 1
Glycaemic responses to metformin monotherapy by SNP clusters in patients with type 2 diabetes
Sheu, W. H., Lee, C., Wang, Y., Liao, C.-S., Hsiao, T., Ken, S., Hatzikotoulas, K., Morris, A. P., Initiative, T. T. 2. D. G. G., Chen, Y. I., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70023 · Cited by 1
“Our results are not unexpected, as the principal glycaemic response to glucose-lowering pharmacological agents is widely recognised to be influenced by pretreatment glycae-mic levels, 39,40 rather than the variants associated with susceptibility alleles for type 2 diabetes.”
Qi, W., Boca, S. M., Boianelli, A., Fredberg, M., Lundqvist, S., Davies, G., Field, J., Brighton, C. A., Snijder, A., Grundevik, P., et al. (2025) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2025.103683 · Cited by 3
IDeglira vs insulin degludec for type 2 diabetes: a systematic review and meta-analysis
Liu, Y., Li, X., Yang, J., Qie, S., Wang, X., Wang, X., & Zheng, Y. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1643386 · Cited by 1
The role of high-protein diets in the management of glycaemic control in people with type 2 diabetes
Whelehan, G., & Stephens, F. B. (2025) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000001161 · Cited by 3
Pieber, T. R., Švehlíková, E., Urva, S., Haupt, A., Zhou, C., Coşkun, T., Höller, V., Fluhr, G., Karanikas, C. A., Miličević, Z., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1627947 · Cited by 4
Cardiovascular benefits of liraglutide in patients with type 2 diabetes: an in-depth exploration
Alluri, A. A., MITRA, A., Marepalli, A., Kshitij, R. A. J., Gandhi, N., Prystupa, Y., & Seetharaman, R. (2025) · Minerva Cardiology and Angiology · doi:10.23736/s2724-5683.25.06846-2 · Cited by 1
Cokro, F., Sauriasari, R., Tahapary, D. L., Setiawan, H., Tricaesario, C., Hidayati, N., & Soegondo, S. (2025) · F1000Research · doi:10.12688/f1000research.163923.3 · Cited by 1
Sabbagh, S., Hegazy, A., Adel, A., Ali, A., Alquddosy, M., Khalid, S., Ibrahim, A. M., Mohamed, A., Mostafa, A., Hassan, A., et al. (2025) · Cureus · doi:10.7759/cureus.92794 · Cited by 6
Soriano, L. C., Moreno-Lostao, A., Calonge, M., Rivas, A., Pulido, J., Colchero, M. C., Artola, S., Serrano, R., Franch‐Nadal, J., & Regidor, E. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106069 · Cited by 3
Anesen, A. A., Cleal, B. R., & Gammeltoft, T. M. (2025) · Sociology of Health & Illness · doi:10.1111/1467-9566.70088 · Cited by 2
Lu, Y., Zhang, R., Yang, J., Liu, D., Wu, Q., Long, X., Cheng, D., Guo, J., Li, Q., Zhang, Y., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-106756 · Cited by 3
Moreira, H. R. S. D., Moreira, F., Jesus, A. M. C., Monteiro‐Soares, M., & Santos, P. (2025) · Diabetology · doi:10.3390/diabetology6100114 · Cited by 2
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Diabetes and benign paroxysmal positional vertigo: A 2-sample Mendelian randomization study
Liu, S. T., Chen, L., Lin, J., et al. (2025) · Medicine · doi:10.1097/md.0000000000045236 · Cited by 1
“[20] The BPPV GWAS dataset includes 486,845 participants (cases = 12,006; controls = 474,839) and 21,326,893 single-nucleotide polymorphisms (SNPs).”
Effect of intermittent fasting on diabetic patients-A narrative review
Ravikoti, S., Bhatia, V., & Mohanasundari, S. K. (2025) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_1992_24 · Cited by 3
“[5] However, these benefits must be weighed against the risks, particularly for individuals taking medications that affect blood sugar.”
Giorgino, F., Taybani, Z. J., CHENG, A. Y. Y., Tebaibia, A., Anaforoğlu, İ., Lauand, F., Servera, S., Li, X., & Fonseca, V. A. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112945 · Cited by 3
EndoCompass project: research roadmap for diabetes, obesity, and metabolism
Mathieu, C., Meireles, M., Pagotto, U., Wabitsch, M., Banerjee, I., Bartolomé, A., Battelino, T., Beck, J., Chiarelli, F., León, D. D. D., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf065 · Cited by 5
Self-citationMykhaylenko, O. Y., & Єлізарова, О. Т. (2025) · Galician Medical Journal · doi:10.21802/e-gmj2025-a27 · Cited by 1
Wang, W. T., & Loh, W. J. (2025) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000940 · Cited by 2
Nakanishi, S., Shimoda, M., Kimura, T., Sanada, J., Fushimi, Y., Iwamoto, Y., Kubo, M., Inaba, R., Okamoto, Y., Iwamoto, H., et al. (2025) · Internal Medicine · doi:10.2169/internalmedicine.6450-25 · Cited by 2
“The cornerstone of disease management is prevention of associated complications, particularly cardiovascular diseases (2).”
Parveen, A., Parveen, S., Vats, N., Shafeeque, M., Choudhary, A., Zaidi, S. A. H., & Yar, M. S. (2025) · Archiv der Pharmazie · doi:10.1002/ardp.70127 · Cited by 4
“Some of these agents like semaglutide, have shown substantial cardiovascular benefits and weight loss potential, making them a pivotal component in the holistic management of type 2 diabetes [18, 19].”
Islam, T., & Uddin, M. N. (2025) · EMJ Diabetes · doi:10.33590/emjdiabet/rkyo7834 · Cited by 1
“29,30 Furthermore, the National Institute for Health and Care Excellence (NICE; UK) has updated, supporting the broader use of SGLT2 inhibitors earlier, particularly for individuals at high cardiovascular or renal risk.”
Moreira, R. O., Nicodemus, N. A., Çömlekçi, A., Yu, M., & Almalki, M. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03394-2 · Cited by 1
Almarhabi, A. S., Alkhari, A. E., Binmahfoz, A., Tawhari, A. O., & Almehwari, S. A. (2025) · Cureus · doi:10.7759/cureus.95899 · Cited by 1
Zhou, L., Li, Y., Zhang, S., Zhang, H., Ji, X., Yu, Y., & Xie, H. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1694982 · Cited by 2
Román-Casiano, K. M., Bermudes-Contreras, J. D., Cornejo‐Garrido, J., Delgado-Alvarado, E. A., Uribe-Soto, J. N., Ruiz‐Baca, E., Gutiérrez-Velázquez, M. V., & Ricario, R. T. (2025) · Future Pharmacology · doi:10.3390/futurepharmacol5040064 · Cited by 2
“For instance, metformin is the preferred first-line medication because of its substantial efficacy in reducing glycated hemoglobin (HbA1c) levels [34].”
Yata, V. K., Das, O. P., Lakshmi, B., Vaishnavi, M., Uddin, M. A., Srikantam, A., & Bukke, S. P. N. (2025) · Scientific Reports · doi:10.1038/s41598-025-22381-9 · Cited by 1
Gao, Y., Zhong, Y., Guan, R., Yu, Q., Liu, H., Tuersun, A., Zhang, Y., Pang, L., Hu, X., & Ma, G. (2025) · Drug Metabolism and Disposition · doi:10.1016/j.dmd.2025.100199 · Cited by 1
Comparison of three types of drugs for cardiovascular and renal benefits in type 2 diabetes mellitus
An, X., Li, X., Zhang, H., Jia, Q.-Y., Zhang, Y., & Yang, G.-G. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.111280 · Cited by 1
Pan, C., Jiang, H., Feng, Y., Wang, S., Zhang, J., Wang, Z., Zhou, Y., Li, F., Zhang, Z., Li, Y., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70305 · Cited by 1
Салухов, В. В., Борисович, Ш. С., & Petrankov, K. V. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-467 · Cited by 2
Sebastian, S. A., Padda, I., Bimal, T., Varma, S., Collins, J. S. P., Ahmad, Z., & Safarova, M. S. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2025.102043 · Cited by 3
DesRochers, P., Kaiser, L., Lee, S., Perchetti, G. A., & Lazarescu, R. (2025) · Cureus · doi:10.7759/cureus.97851 · Cited by 1
Erande, S. G., Agrawal, M., Gulati, S., Jagtap, N., Kumar, N. S. P., Kapoor, V. K., Bhushan, S., Gadkari, R., Jadhav, M., CHOUDHARI, S. Y., et al. (2025) · Cardiovascular Diabetology – Endocrinology Reports · doi:10.1186/s40842-025-00244-6 · Cited by 1
van Dijk, P. R., Chesters, C., Timmons, J., Szafranski, K., Bakker, J., & Levrat‐Guillen, F. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01821-9 · Cited by 2
Malighetti, M. E., Vescini, F., Carpentieri, M. S., Altomari, A., Turchi, F., Porto, A. D., & Dauriz, M. (2025) · Minerva Endocrinology · doi:10.23736/s2724-6507.25.04376-3 · Cited by 1
Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes
Choi, S., Seo, J., Park, S., Kim, N. Y., Kim, H., & Lim, H.-S. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1715585 · Cited by 2
Escamilla-Núñez, C., Rojas, R., Aguilar-Salinas, C. A., Martínez, M. R., Almeda‐Valdés, P., & Castro-Porras, L. V. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02043-6 · Cited by 1
“In particular, for sleep disturbances, different authors have linked them to metabolic disorders [29, 30].”
Rias, Y. A., Akasyah, W., Mulyati, T. A., Astuti, H. W., Noronha, H., Sani, F. N., & Tsai, H. (2025) · Journal of Preventive Medicine and Public Health · doi:10.3961/jpmph.25.334 · Cited by 1
Clinical, functional and cognitive features of late-onset multiple sclerosis
Tedone, N., Preziosa, P., Meani, A., Mistri, D., Esposito, F., Rocca, M. A., & Filippi, M. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13550-x · Cited by 2
Wu, R., Xing, B., Zhou, Z., Yu, L., & Wang, H. (2025) · Neurological Sciences · doi:10.1007/s10072-025-08680-z · Cited by 1
Lang, M. V., Vasu, P., Dorairaj, E. A., Bhartiya, S., & Dorairaj, S. K. (2025) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10078-1501 · Cited by 2
Lee, S., Han, K. A., Hong, E., Kang, J. G., Chung, C. H., Won, J. C., Jeon, E. J., Cho, J. H., Cho, H., Kim, S. G., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70386 · Cited by 2
“2,3 The treatment strategy of combining multiple drugs with different mechanisms of action could lead to more stable glycemic con-trol and help prevent or delay diabetic complications.”
Bajpai, J., Saxena, M., Agarwal, U., & Pradhan, A. (2025) · World Journal of Experimental Medicine · doi:10.5493/wjem.v15.i4.109762 · Cited by 1
Wan, Y., Qian, X., Zhang, W., Dong, Y., Huang, Y., Qin, W., Bai, J., & Dong, A. (2025) · Global Health & Medicine · doi:10.35772/ghm.2025.01119 · Cited by 2
Merker, L., Ebert, T., Schleicher, E. D., Isermann, B. H., & Guthoff, M. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-8500 · Cited by 2
Cardiovascular Disease and Diabetes: A New Challenge in the Treatment and Management
Riccioni, G., Notarangelo, C., Riccioni, M., & D’Orazio, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms27010354 · Cited by 1
Visentin, S., Béliard, S., Cécile, R., Caussy, C., Hamidou, Z., David, R., Mélanie, G., Petit, A., Saultier, P., Patrick, B., et al. (2026) · Pediatric Blood & Cancer · doi:10.1002/1545-5017.70040 · Cited by 1
“Medications used in diabetic patients (such as metformin, glucagon-like-peptide-1-agonist, and sodium-glucose cotransporter-2 inhibitors [ 49 ]) may benefit these patients in the long term, by improving insulin resistance and reducing MASLD [ 44 ].”
Chen, L., Lv, L., Zhang, Z., & Jiang, S. (2026) · Actas Urológicas Españolas (English Edition) · doi:10.1016/j.acuroe.2026.501901 · Cited by 1
Peng, J., Xue, D., Li, J., Wei, L., & Wang, Y. (2026) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s573535 · Cited by 1
Alday, I. H., Jiménez‐Díaz, J., Ganga, C. S. L., Hierro, J. G., Enríquez, A. J., Barrena, A. S., Gamazo, J. P., Lobariñas, L. E. L., Tapia-Sanchiz, M. S., Carrera, M. A., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2025.12.023 · Cited by 1
Oshakbayev, K., Durmanova, A., Kuttymuratov, G., Bikhanov, N., Nabiyev, A., Suleimenov, T., Idrisov, A., Shakhmarova, T., Mirmanova, Z., Rakhimova, S., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15020546 · Cited by 1
“Diagnosis of T2DM according to the criteria of the World Health Organization and International Diabetes Federation (WHO/IDF consultation in 2006) [42]: HbA1c ≥ 6.5% (47.5 mmol/mol), fasting plasma glucose ≥ 7.0 mmol/L, or a patient receives antidiabetic therapy (American Diabetes Association) [30].”
InfluentialWang, W., Samadbeik, M., Puri, G., McLeod, D. S. A., Lobo, E. H., Quang, T. D., Kirwa, T., & Sullivan, C. M. (2026) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2026.106275 · Cited by 1
Ke, W., Liu, L., Zhang, P., Yan, L., Zhang, Q., Zhang, F., Xu, X., Liu, J., Xu, L., Wan, X., et al. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70187 · Cited by 3
Akmal, M., Tariq, S., Mustafa, M., et al. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70399 · Cited by 1
“As in previous studies, 2,14 – 18 direct head-to-head evidence comparing efsitora with icodec is lacking, restricting conclusions about comparative effectiveness.”
Ali, H., Agwu, E., Ali, M., Jama, Y. M., Ahmed, A. A. S., Yusuf, M. A., Araye, A. A., Osobow, I. M., Sandeyl, A. A., Ahmed, Z., et al. (2026) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s562440 · Cited by 2
Vasquez-Martínez, N., Trapala, J., Álvarez‐Añorve, L. I., Lizárraga-Valadez, R. A., González‐Andrade, M., & Sosa‐Peinado, A. (2026) · ACS Omega · doi:10.1021/acsomega.5c08231 · Cited by 2
Lund, N., Maslova, E., Chen, J., Giannini, J., Soro, M. B., Culligan, I., Richards, G., Taneja, L., Varghese, S., Li, Y., et al. (2026) · BMJ Open · doi:10.1136/bmjopen-2025-106299 · Cited by 2
Retrospective chart review on psychiatric manifestations of GLP-1 agonist usage
Sa, B., Maristany, A. J., Subramaniam, A., Kumbkarni, N., Lange, R., Oldak, S. E., Buciuc, A. G., & Padilla, V. L. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.01.042 · Cited by 3
A Closed-Form Cubic–Logistic Approximation to the Normal Cumulative Distribution Function
Frölich, M. A. (2026) · Mathematics · doi:10.3390/math14030486 · Cited by 1
Shlomov, T., Nitzan, I., Pollack, R. M., Zloto, O., & Gur, Z. (2026) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2026.01.010 · Cited by 2
Chen, H., Chen, H., Yao, Y., Liu, M., & Xiong, X. (2026) · BMC Geriatrics · doi:10.1186/s12877-026-07080-y · Cited by 1
“Similarly, this framing echoes diabetes care, where clinicians balance hyper-glycaemia control with hypoglycaemia prevention [28].”
Chandra, K. P., GUPTA, M., Awasthi, R., Pande, A. R., Gupta, N., Kumar, D., Agarwal, V., Gupta, T., AWASTHI, S., & Lachhwani, H. (2026) · Cureus · doi:10.7759/cureus.102866 · Cited by 2
Fathi, A. E., Nass, R. M., Levy, C. J., Levister, C. M., O’Malley, G., Shah, N. A., Hassan, S., Quainoo, C., Koravi, C. L. K., NGUYEN, T., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261420193 · Cited by 1
Mellanen, E. H., Kauppila, T., Kautiainen, H., Lehto, M. T., Rahkonen, O., Pitkälä, K. H., & Laine, M. K. (2026) · Primary care diabetes · doi:10.1016/j.pcd.2026.02.002 · Cited by 1
Петрухина, И. К., Lazarev, A. M., Ryazanova, T. K., et al. (2026) · FARMAKOEKONOMIKA Modern Pharmacoeconomics and Pharmacoepidemiology · doi:10.17749/2070-4909/farmakoekonomika.2026.323 · Cited by 1
Milushewa, P., Chenesheva, N., & Petkova, V. B. (2026) · Pharmacy · doi:10.3390/pharmacy14010035 · Cited by 1
“Contemporary guidelines emphasize the importance of individualized treatment plans, incorporating agents such as GLP-1 receptor agonists and SGLT-2 inhibitors for their demonstrated cardio-renal benefits, especially in patients with comorbidities [6,7].”
O’Brien, R. C., Abdallah, K., Dong, X., Hassanein, M. M., Ji, Q., Keşkek, Ş. Ö., López-Jaramillo, P. A., Mehta, R., Raef, H., & Tan, K. (2026) · Journal of Diabetes · doi:10.1111/1753-0407.70193 · Cited by 3
Vournas, G., Mourgos, L., Doumas, M. N., Liberopoulos, E. N., Kotsa, K., & Koufakis, T. (2026) · Diseases · doi:10.3390/diseases14020075 · Cited by 2
“In parallel, sodium–glucose cotransporter-2 inhibitors (SGLT2i) are recommended for those with heart failure or chronic kidney disease (CKD) [11–13].”
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.